SHANXI PHARMA<00327> - Amendment to Results Announcement (advised by SHANXI PHARMA)

The Stock Exchange has received a message from Shanxi Central 
Pharmaceutical International Limited which is reproduced as follows:-

"With regard to the figure of "Profit/(loss) from Operations" in the last 
corresponding period (i.e. June 1, 2001 to May 31, 2002) in the Results 
Announcement Form (The "Summary"), it should actually mean profit after 
finance costs. Thus, we would like to rectify the figure on the attached 
form for this item to HK$49,667,000 and the figure of "Finance cost" 
should be "nil".

Regarding the Company's press announcement and annual report for 2001, the 
term "Profit/(loss) from Operations" also means profit after finance 
costs. As the finance cost for the year ended May 31, 2001 is 
immaterial, we did not present the item separately on the financial 
statements. However, when we submitted the Summary last year, we were 
required by the Stock Exchange to separate the item of "Finance cost" 
regardless if it is immaterial or not.

To be consistenet with the figures presented on the Company's press 
announcement and annual report for 2001, the Company would like to change 
the figures reported in the revised Summary."